Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist that was originally developed for type 2 diabetes management and subsequently approved by the FDA for chronic weight management under the brand name Wegovy
Mast cell stabilizer (MCAS Connection): GLP-1 receptors are also found on mast cells, and recent studies have shown that GLP-1 RA drugs prevent overactive mast cell degranulation
Frustrating providers, frustrating patients. While there is a lot of media attention on these medications as part of the solution, they are not new
and scientific advisory boards for Eli Lilly, Novo Nordisk, Amgen, Pfizer, Currax, Calibrate, Vida Health, Ilant Health, Mellicell, Sweetch, Doximity, GoodRx, Empros Pharma, Clearmind Medicine, and Apnimed.The other authors report no disclosures
Simard, L